.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Indian government has officially reaffirmed the India e-cigarette ban, dealing a significant blow to Philip Morris International. Specifically, the Ministry of Health ruled out any relaxation of the 2019 law that prohibits electronic nicotine delivery systems. This decision follows years of intense private lobbying by the tobacco giant to permit its heat-not-burn (HNB) device, IQOS. Consequently, India remains one of the strictest markets globally regarding alternative tobacco products.
Notably, the government emphasizes that its stance is rooted in evidence-based tobacco control measures. Therefore, New Delhi intends to prevent a new wave of nicotine addiction among the youth. Tobacco currently kills more than a million people in India every year. Although Philip Morris argues that IQOS is less harmful than traditional cigarettes, the World Health Organization (WHO) warns of substantial risks. Furthermore, the Indian Council of Medical Research (ICMR) confirmed it has no plans to research these products.
Meanwhile, Philip Morris executives lobbied top officials and parliamentary panels from 2021 to 2025. They requested scientific reviews and exemptions for heat-not-burn products. Specifically, they proposed that India should adopt harm-reduction policies similar to those for HIV/AIDS. However, the health ministry stated that the law explicitly bans such devices. Since India is the world\'s seventh-largest cigarette market, the stakes for tobacco firms are incredibly high. Additionally, other countries like Vietnam have recently strengthened their own bans on these products.
Q1: Does the India e-cigarette ban include heat-not-burn (HNB) products?
Yes, the Ministry of Health has clarified that the 2019 Prohibition of Electronic Cigarettes Act explicitly covers all heat-not-burn tobacco devices.
Q2: Why did India reject the proposal to allow IQOS?
The government rejected the proposal to prioritize public health and prevent nicotine addiction, citing a lack of local research and warnings from international health bodies like the WHO.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India maintains its firm ban on e-cigarettes and heat-not-burn products like IQOS, rejecting years of lobbying by Philip Morris to prioritize public health....
6 months ago
A landmark study analyzing over 56,000 adult health records in Delhi-NCR reveals that hypertension and diabetes coexistence affects nearly 5% of adults. The prevalence doubles expected rates and rises sharply after age 40. Early integrated screening is essential to prevent microvascular and macrovascular complications.
Today
An overview of surrogacy laws in India and global regulations, analyzing the transition to altruistic surrogacy, eligibility criteria, international cross-border challenges, and clinical compliance requirements for healthcare providers.
Today
A multicenter J-CASE survey study reveals that left ventricular apical longitudinal strain (LV-apical LS) independently predicts all-cause death in patients with immunoglobulin light-chain (AL) cardiac amyloidosis, establishing an optimal prognostic cut-off threshold of 15.9%.
Today
Researchers developed a Haversian-inspired composite scaffold that addresses delayed vascularization and wet-state mechanical deterioration in critical bone defect repair. By integrating spatially programmed calcium phosphate minerals and selective silica reinforcement, the design promotes vascularized bone repair.
Yesterday
A study of hospitalized adult patients with severe eating disorders revealed that while serum leptin increases linearly with weight gain during early refeeding, thyroid hormones show a biphasic trajectory. Low T3 and undetectable leptin frequently persist at discharge, highlighting delayed endocrine recovery.
Today
